Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorJackson, Kateen_US
dc.contributorAshby, Michaelen_US
dc.contributorMartin, Peteren_US
dc.contributorPisasle, Mariaen_US
dc.contributorBrumley, Daviden_US
dc.contributorHayes, Barbaraen_US
dc.description.abstractThe results of a novel approach to the use of ketamine in refractory cancer pain are reported. In this prospective, multicenter, unblinded, open-label audit, 39 patients (with a total of 43 pains) received a short duration (3 to 5 days) ketamine infusion. The initial dose of 100 mg/24 hr was escalated if required to 300 mg/24 hr and then to a maximum dose of 500 mg/24hr. The overall response rate was 29/43 (67%). Analysis of results according to pain mechanisms showed that 15/17 somatic and 14/23 neuropathic pains responded. In 5 patients who appeared to respond, it is possible that another concurrent intervention may have contributed in whole or part for the pain relief observed. After cessation of ketamine, 24/29 maintained good pain control, with a maximum documented duration of eight weeks. However, 5 of the initial 29 responders experienced a recurrence of pain within 24 hours, and ketamine was recommenced. Of these, 2 underwent another intervention for pain control while 3 continued on ketamine until their deaths between two and four weeks later. Twelve patients reported adverse psychomimetic effects, with the incidence rising with increasing dose. Four of these were non-responders and the ketamine was stopped. Eight were responders, and in 3 the adverse effects were rendered acceptable with dose reduction; the other 5 rejected a dose reduction. The results reported suggest the need for further investigation of the place of ketamine in cancer pain management.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2018-09-06T04:50:07Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2018-09-06T04:50:30Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2018-09-06T04:50:30Z (GMT). No. of bitstreams: 0 Previous issue date: 2001en
dc.title“Burst” ketamine for refractory cancer pain: an open-label audit of 39 patients.en_US
dc.typeJournal Articleen_US
dc.bibliographicCitation.titleJournal of Pain and Symptom Managementen_US
dc.subject.healththesaurusCANCER PAINen_US
dc.subject.healththesaurusPALLIATIVE CAREen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.